<?xml version="1.0" encoding="UTF-8"?>
<ref id="B62-cells-08-00666">
 <label>62.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Di Maio</surname>
    <given-names>V.C.</given-names>
   </name>
   <name>
    <surname>Cento</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Lenci</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Aragri</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Rossi</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Barbaliscia</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Melis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Verucchi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Magni</surname>
    <given-names>G.F.</given-names>
   </name>
   <name>
    <surname>Teti</surname>
    <given-names>E.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies</article-title>
  <source>Liver Int.</source>
  <year>2017</year>
  <volume>37</volume>
  <fpage>514</fpage>
  <lpage>528</lpage>
  <pub-id pub-id-type="doi">10.1111/liv.13327</pub-id>
  <?supplied-pmid 28105744?>
  <pub-id pub-id-type="pmid">28105744</pub-id>
 </element-citation>
</ref>
